ZL-99

ZL-99 is a small-molecule dual inhibitor targeting the MAPK signaling pathway, specifically inhibiting both MEK (mitogen-activated protein kinase kinase) and RAF (rapidly accelerated fibrosarcoma) kinases. Developed by Chengdu Zenitar Biomedical Technology, ZL-99 is designed to treat cancers driven by MAPK pathway activation, including Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), and Serous Ovarian Cancer (SOC). By simultaneously targeting two critical nodes within the RAS/RAF/MEK/ERK cascade, ZL-99 aims to provide more robust pathway suppression and potentially mitigate the emergence of resistance compared to single-agent inhibition of either MEK or RAF alone.